Reactions and commentary on breaking clinical and health economic data presented at top conferences and their impact on practice and policy.
December 6th 2024AHA 2024 Key Takeaways: Innovations in Managing Heart Failure
Orly Vardeny, PharmD, MS, discusses how glucagon-like peptide-1 receptor agonists demonstrate multiple cardioprotective mechanisms including reduced inflammation, improved glucose metabolism, and enhanced endothelial function, while clinical trials of both finerenone and ferric carboxymaltose evaluate specific outcomes in patients with heart failure through rigorous study protocols.
November 12th 2024CHEST 2024 Key Takeaways: Innovations in IPF and PAH
Steven Nathan, MD, discusses how key findings from CHEST 2024, including survival predictors from the IPF-PRO Registry and the potential of inhaled treprostinil for CTD-PAH, are shaping new approaches to managing IPF and PAH, with a focus on early diagnosis, personalized treatments, and improving patient outcomes.
July 12th 2024ASCO 2024: Advances in Non-Small Cell Lung Cancer
A key opinion leader analyzes pivotal non-small cell lung cancer trials presented at ASCO 2024, including LAURA, CHRYSALIS-2, TROPION-Lung05, and CheckMate 9LA, discussing their implications for treatment strategies in non-small cell lung cancer.